Department of Gynecology and Obstetrics, State University of Campinas, Campinas, Brazil.
Department of Maternal and Child Health, Federal University of Pernambuco, Recife, Brazil.
BMJ Open. 2020 Dec 29;10(12):e040652. doi: 10.1136/bmjopen-2020-040652.
Hypertension is a very important cause of maternal morbidity and mortality worldwide, despite efforts on prevention. The lack of a tool to provide effective and early prediction of hypertension for a high-risk group may contribute to improving maternal and fetal outcomes. Metabolomics has figured out as a promised technology to contribute to the improvement of hypertension in pregnancy prediction.
Our primary outcome is hypertensive disorders of pregnancy. A detailed systematic literature search will be performed in electronic databases PubMed, EMBASE, Scopus, Web of Science, Latin America and Caribbean Health Sciences Literature, Scientific Electronic Library Online, Health Technology Assessment and Database of Abstracts of Reviews of Effects using controlled terms 'pre-eclampsia', 'hypertensive disorders', 'metabolomics' and 'prediction' (and their variations). Studies from the latest 20 years will be included, except case reports, reviews, cross-sectional studies, letter to editors, expert opinions, commentaries papers or non-human research. If possible, we will perform a meta-analysis. Two peer-reviewers will independently perform the search and in cases of discordance, a third reviewer will be consulted.
As a systematic review, ethics approval is not required. The results of this review will present the current use and performance of metabolomics for predicting gestational hypertension. Such data could potentially guide future studies and interventions to improve existing prediction models.
CRD42018097409.
尽管在预防方面做出了努力，但高血压仍是全球孕产妇发病率和死亡率的一个重要原因。缺乏一种工具来为高危人群提供有效的早期高血压预测，这可能有助于改善母婴结局。代谢组学已成为提高妊娠高血压预测能力的一项有前途的技术。
我们的主要结局是妊娠高血压疾病。将在电子数据库 PubMed、EMBASE、Scopus、Web of Science、拉丁美洲和加勒比健康科学文献、科学电子图书馆在线、卫生技术评估和效应摘要数据库中使用受控术语“先兆子痫”、“高血压疾病”、“代谢组学”和“预测”（及其变体）进行详细的系统文献检索。除病例报告、综述、横断面研究、给编辑的信、专家意见、评论文章或非人类研究外，将纳入最近 20 年的研究。如果可能，我们将进行荟萃分析。两位同行评审员将独立进行检索，如果意见不一致，将咨询第三位评审员。
由于这是一项系统评价，因此不需要伦理批准。本综述的结果将展示代谢组学在预测妊娠高血压方面的当前应用和性能。这些数据可能有助于指导未来的研究和干预措施，以改进现有的预测模型。
PROSPERO 注册号：CRD42018097409。
